Shares of Guardant Health, Inc. (NASDAQ:GH – Get Rating) have earned a consensus recommendation of “Moderate Buy” from the nineteen research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $90.39.
Several equities analysts have recently issued reports on GH shares. Craig Hallum started coverage on Guardant Health in a research note on Wednesday, October 19th. They issued a “buy” rating and a $88.00 price objective for the company. The Goldman Sachs Group cut their target price on Guardant Health from $80.00 to $70.00 and set a “buy” rating on the stock in a research report on Friday, November 4th. Cowen cut their target price on Guardant Health from $110.00 to $83.00 in a research report on Friday, November 4th. Bank of America raised their target price on Guardant Health from $65.00 to $70.00 in a research report on Friday, December 16th. Finally, Stephens cut their target price on Guardant Health from $99.00 to $90.00 and set an “overweight” rating on the stock in a research report on Monday, November 7th.
Insiders Place Their Bets
In other news, insider Kumud Kalia sold 3,125 shares of the business’s stock in a transaction that occurred on Tuesday, November 15th. The stock was sold at an average price of $51.87, for a total value of $162,093.75. Following the transaction, the insider now owns 20,135 shares of the company’s stock, valued at $1,044,402.45. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 5.90% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
Guardant Health Stock Performance
Shares of GH opened at $30.43 on Monday. The stock has a 50-day simple moving average of $39.99 and a 200-day simple moving average of $46.95. The company has a debt-to-equity ratio of 6.82, a quick ratio of 6.10 and a current ratio of 6.46. The stock has a market capitalization of $3.12 billion, a PE ratio of -5.13 and a beta of 0.83. Guardant Health has a 1 year low of $24.63 and a 1 year high of $79.24.
Guardant Health (NASDAQ:GH – Get Rating) last announced its quarterly earnings data on Thursday, November 3rd. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.31). The company had revenue of $117.40 million during the quarter, compared to analysts’ expectations of $118.18 million. Guardant Health had a negative net margin of 140.58% and a negative return on equity of 145.58%. On average, analysts predict that Guardant Health will post -6.46 earnings per share for the current fiscal year.
Guardant Health Company Profile
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients.
- Get a free copy of the StockNews.com research report on Guardant Health (GH)
- General Electric Stock, The Sum of All Parts Strategy is Paying Off
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here’s Why
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.